English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT

Released

Journal Article

Correction of amygdalar dysfunction in a rat model of fragile X syndrome

MPS-Authors

Donlin-Asp,  Paul G.
Synaptic Plasticity Department, Max Planck Institute for Brain Research, Max Planck Society;

/persons/resource/persons208206

Schuman,  Erin M.
Synaptic Plasticity Department, Max Planck Institute for Brain Research, Max Planck Society;

External Resource
Fulltext (restricted access)
There are currently no full texts shared for your IP range.
Fulltext (public)

1-s2.0-S2211124721012651-main.pdf
(Publisher version), 4MB

Supplementary Material (public)
There is no public supplementary material available
Citation

Fernandes, G., Mishra, P. K., Sarfaraz Nawaz, M., Donlin-Asp, P. G., Mohammed, M. R., Hazra, A., et al. (2021). Correction of amygdalar dysfunction in a rat model of fragile X syndrome. Cell Rep., 37(2): 109805. doi:10.1016/j.celrep.2021.109805.


Cite as: https://hdl.handle.net/21.11116/0000-0009-8454-3
Abstract
Fragile X syndrome (FXS), a commonly inherited form of autism and intellectual disability, is associated with emotional symptoms that implicate dysfunction of the amygdala. However, current understanding of the pathogenesis of the disease is based primarily on studies in the hippocampus and neocortex, where FXS defects have been corrected by inhibiting group I metabotropic glutamate receptors (mGluRs). Here, we observe that activation, rather than inhibition, of mGluRs in the basolateral amygdala reverses impairments in a rat model of FXS. FXS rats exhibit deficient recall of auditory conditioned fear, which is accompanied by a range of in vitro and in vivo deficits in synaptic transmission and plasticity. We find presynaptic mGluR5 in the amygdala, activation of which reverses deficient synaptic transmission and plasticity, thereby restoring normal fear learning in FXS rats. This highlights the importance of modifying the prevailing mGluR-based framework for therapeutic strategies to include circuit-specific differences in FXS pathophysiology.